- Home
- DAVE vs CVAC Comparison
DAVE vs CVAC Comparison
Compare DAVE & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVE
- CVAC
- Stock Information
- Founded
- DAVE 2017
- CVAC 2000
- Country
- DAVE United States
- CVAC Germany
- Employees
- DAVE N/A
- CVAC N/A
- Industry
- DAVE Retail: Computer Software & Peripheral Equipment
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- DAVE Technology
- CVAC Health Care
- Exchange
- DAVE Nasdaq
- CVAC Nasdaq
- Market Cap
- DAVE 795.6M
- CVAC 637.1M
- IPO Year
- DAVE N/A
- CVAC 2020
- Fundamental
- Price
- DAVE $102.92
- CVAC $2.90
- Analyst Decision
- DAVE Strong Buy
- CVAC Hold
- Analyst Count
- DAVE 6
- CVAC 3
- Target Price
- DAVE $96.50
- CVAC $10.00
- AVG Volume (30 Days)
- DAVE 493.4K
- CVAC 523.1K
- Earning Date
- DAVE 11-12-2024
- CVAC 11-12-2024
- Dividend Yield
- DAVE N/A
- CVAC N/A
- EPS Growth
- DAVE N/A
- CVAC N/A
- EPS
- DAVE 3.12
- CVAC N/A
- Revenue
- DAVE $319,355,000.00
- CVAC $70,565,734.00
- Revenue This Year
- DAVE $30.69
- CVAC $738.59
- Revenue Next Year
- DAVE $20.47
- CVAC N/A
- P/E Ratio
- DAVE $33.33
- CVAC N/A
- Revenue Growth
- DAVE 30.00
- CVAC 75.11
- 52 Week Low
- DAVE $7.73
- CVAC $2.22
- 52 Week High
- DAVE $108.50
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- DAVE 70.23
- CVAC 46.81
- Support Level
- DAVE $82.18
- CVAC $2.85
- Resistance Level
- DAVE $108.50
- CVAC $3.56
- Average True Range (ATR)
- DAVE 8.46
- CVAC 0.17
- MACD
- DAVE 0.13
- CVAC -0.01
- Stochastic Oscillator
- DAVE 83.49
- CVAC 14.56
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit, and finding side gigs.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.